Levalbuterol Solution
Product Images NDC 63187-953

15 FDA label images from Proficient Rx Lp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Levalbuterol (NDC 63187-953). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Image 01)

Chemical Structure (Image 01)
Chemical structure of Levalbuterol hydrochloride, showing its molecular configuration including benzene ring, hydroxyl groups, and an amine moiety with adjacent hydrochloride ion.*
FDA Label Image

Figure 1 (Image 02)

Figure 1 (Image 02)
A line graph showing mean change in FEV1 (%) over time (hours) for four groups: Lev 1.25, Lev 0.63, Rac 2.5, and PBO. The graph illustrates the response trends of respiratory treatments with data points from 0 to 8 hours, including a horizontal marker at 15% change.*
FDA Label Image

Figure 2 (Image 03)

Figure 2 (Image 03)
A line graph depicting mean change in FEV1 (%) over an 8-hour period comparing Levalbuterol at 1.25 mg and 0.63 mg, Racemic albuterol 2.5 mg, and placebo (PBO). The x-axis shows time in hours, and the y-axis shows percentage change in FEV1, with several curves illustrating the response over time for each treatment group.*
FDA Label Image

Figure 3 (Image 04)

Figure 3 (Image 04)
A line graph showing mean change in FEV1 (%) over time (hours) for different treatments: Lev 0.63, Lev 0.31, Rac 2.5, Rac 1.25, and Pbo. Each line represents one treatment group with sample sizes noted. The graph tracks respiratory function changes up to 4 hours after administration.*
FDA Label Image

Figure 4 (Image 05)

Figure 4 (Image 05)
A line graph showing mean change in FEV1 (%) over time (hours) for different treatments: Levalbuterol 0.63 mg, Levalbuterol 0.31 mg, Racemic albuterol 2.5 mg and 1.25 mg, and placebo. The graph depicts FEV1 percentage change increasing sharply within the first hour, plateauing, and then gradually decreasing over 4 hours.*
FDA Label Image

Figure A (Image 06)

Figure A (Image 06)
An instructional illustration showing a vial with a designated shaded area labeled as the "twist-off tab portion". The vial is marked with "TWIST OFF TAB" on both sides above the shaded region, indicating where the vial should be twisted to open.*
FDA Label Image

Figure B (Image 07)

Figure B (Image 07)
An instructional illustration showing the top edge of a medication pouch with a labeled tear seam, indicating where to open the package by tearing at the designated seam.*
FDA Label Image

Figure C (Image 08)

Figure C (Image 08)
A black and white line drawing showing a hand holding a small vial or ampule with a scored neck, demonstrating the step of snapping off the top of the vial by bending it backward to open.*
FDA Label Image

Figure D (Image 09)

Figure D (Image 09)
An instructional illustration depicting the insertion of a vial into a reservoir, likely demonstrating how to prepare a respiratory inhalation solution for use. The vial is oriented above the labeled reservoir, with a hand holding the vial, indicating the correct positioning for assembly.*
FDA Label Image

Figure E.1 (Image 10)

Figure E.1 (Image 10)
An instructional diagram showing parts of a respiratory inhalation solution delivery device labeled as 'Mouthpiece' and 'Reservoir.' The illustration highlights the mouthpiece component detached from the main reservoir unit of the device.*
FDA Label Image

Figure E.2 (Image 11)

Figure E.2 (Image 11)
An instructional illustration showing a face mask and a reservoir, with an arrow indicating the flow or connection between the face mask and the reservoir, likely related to the use of an inhalation solution device.*
FDA Label Image

Figure F (Image 12)

Figure F (Image 12)
An instructional diagram showing a connector labeled 'NEBULIZER TUBING' being attached to a medical device labeled 'COMPRESSOR.' This depicts part of the setup for a nebulizer system used for respiratory inhalation therapy.*
FDA Label Image

Figure G.1 (Image 13)

Figure G.1 (Image 13)
An instructional diagram showing a person using a respiratory inhalation device with labeled parts: mouthpiece and reservoir. The illustration demonstrates proper placement of the mouthpiece into the mouth for inhalation of the solution.*
FDA Label Image

Figure G.2 (Image 14)

Figure G.2 (Image 14)
An instructional diagram illustrating the use of a respiratory inhalation solution device with a face mask and reservoir. The diagram labels the 'FACE MASK' and 'RESERVOIR' components, showing how the face mask fits over the reservoir mouthpiece for administration.*
FDA Label Image

63187-953-24 (Image 17)

63187-953-24 (Image 17)
Label for Levalbuterol 0.63 mg/3 mL inhalation solution, containing 24 unit-dose vials. Labeled for prescription use and manufactured by Norton Healthcare Limited T/A IVAX Pharmaceuticals UK. Relabeled by Proficient Rx LP, Thousand Oaks, CA. Storage instructions and lot/expiration placeholders are shown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.